LEXX — Lexaria Bioscience Balance Sheet
0.000.00%
- $23.70m
- $16.78m
- $0.46m
Annual balance sheet for Lexaria Bioscience, fiscal year end - August 31st, USD millions except per share, conversion factor applied.
R2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-Q | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1.31 | 11.8 | 6.16 | 1.48 | 6.56 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.209 | 0.342 | 0.202 | 0.175 | 0.154 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1.93 | 12.4 | 6.98 | 2.2 | 7.9 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.61 | 0.459 | 0.368 | 0.422 | 0.39 |
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Total Assets | 2.83 | 13.3 | 7.83 | 3.08 | 8.87 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.226 | 0.153 | 0.194 | 0.268 | 1.1 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.303 | 0.001 | -0.115 | 0.04 | 0.831 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 2.53 | 13.3 | 7.95 | 3.04 | 8.04 |
Total Liabilities & Shareholders' Equity | 2.83 | 13.3 | 7.83 | 3.08 | 8.87 |
Total Common Shares Outstanding |